Literature DB >> 18182458

Plasticity of dendritic cell function in response to prostaglandin E2 (PGE2) and interferon-gamma (IFN-gamma).

Manfred Lehner1, Andrea Stilper, Patrick Morhart, Wolfgang Holter.   

Abstract

Current evidence suggests that maturing dendritic cells (DCs) acquire a migratory phenotype to induce T cell responses in lymph nodes or a proinflammatory phenotype to condition the microenvironment at peripheral sites. We show that the interplay of PGE(2) and IFN-gamma generates a more complex pattern of mixed DC phenotypes in response to TLR stimulation. DCs activated by the TLR ligand R-848 in the presence of IFN-gamma and PGE(2) produced high levels of IL-12p70 and IL-23, started migration toward CCL19 within only 10 h, and still continued to secrete IL-12p70 without further restimulation following the migration step. The accelerated onset of migration was a result of PGE(2) and was associated with reduced plastic adherence and lower amounts of activated CD29. In contrast, IFN-gamma by itself enhanced cell adhesion and strongly hindered CCR7-mediated migration in the absence of PGE(2). This suggests a new role for IFN-gamma in the direct regulation of DC migration through enhanced cell adhesion, perhaps to support the development of T cell effector functions at peripheral sites. Together, our data are relevant to the development of DC vaccines, as they demonstrate the existence of dual-functional DCs, which as a result of the simultaneous effects of PGE(2) and IFN-gamma, can migrate rapidly toward lymph node chemokines and carry with them a wave of primary cytokines.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18182458     DOI: 10.1189/jlb.0307153

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  7 in total

1.  Human Primary Immune Cells Exhibit Distinct Mechanical Properties that Are Modified by Inflammation.

Authors:  Nathalie Bufi; Michael Saitakis; Stéphanie Dogniaux; Oscar Buschinger; Armelle Bohineust; Alain Richert; Mathieu Maurin; Claire Hivroz; Atef Asnacios
Journal:  Biophys J       Date:  2015-05-05       Impact factor: 4.033

2.  Plasma membrane proteomes of differentially matured dendritic cells identified by LC-MS/MS combined with iTRAQ labelling.

Authors:  Stéphanie Ferret-Bernard; William Castro-Borges; Adam A Dowle; David E Sanin; Peter C Cook; Joseph D Turner; Andrew S MacDonald; Jerry R Thomas; Adrian P Mountford
Journal:  J Proteomics       Date:  2011-10-25       Impact factor: 4.044

3.  Low CCR7-mediated migration of human monocyte derived dendritic cells in response to human respiratory syncytial virus and human metapneumovirus.

Authors:  Cyril Le Nouën; Philippa Hillyer; Christine C Winter; Thomas McCarty; Ronald L Rabin; Peter L Collins; Ursula J Buchholz
Journal:  PLoS Pathog       Date:  2011-06-23       Impact factor: 6.823

Review 4.  Optimizing dendritic cell-based immunotherapy: tackling the complexity of different arms of the immune system.

Authors:  Ilse Van Brussel; Zwi N Berneman; Nathalie Cools
Journal:  Mediators Inflamm       Date:  2012-07-18       Impact factor: 4.711

5.  Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling.

Authors:  Katia Boniface; Kristian S Bak-Jensen; Ying Li; Wendy M Blumenschein; Mandy J McGeachy; Terrill K McClanahan; Brent S McKenzie; Robert A Kastelein; Daniel J Cua; René de Waal Malefyt
Journal:  J Exp Med       Date:  2009-03-09       Impact factor: 14.307

6.  Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy.

Authors:  Katerina Vopenkova; Klara Mollova; Ivana Buresova; Jaroslav Michalek
Journal:  J Cell Mol Med       Date:  2012-11       Impact factor: 5.310

7.  Long-Term Exposure to Inflammation Induces Differential Cytokine Patterns and Apoptosis in Dendritic Cells.

Authors:  Laura Stentoft Carstensen; Olivia Lie-Andersen; Andreas Obers; Michael Douglas Crowther; Inge Marie Svane; Morten Hansen
Journal:  Front Immunol       Date:  2019-11-21       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.